- |||||||||| fluoxetine / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: SMART: Fluoxetine Vs CBT in Childhood Anxiety Disorders (clinicaltrials.gov) - May 15, 2024
P3, N=316, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2024
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Phase classification, Enrollment change, Trial completion date, Trial withdrawal, Adverse events: A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique (clinicaltrials.gov) - May 15, 2024
P2, N=0, Withdrawn,
Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2024 Phase classification: P2b --> P2 | N=200 --> 0 | Trial completion date: May 2025 --> Sep 2025 | Not yet recruiting --> Withdrawn
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial primary completion date: Botox or Botox With Esophageal Dilation in Patients With Achalasia (clinicaltrials.gov) - May 15, 2024
P4, N=50, Enrolling by invitation,
Phase classification: P2b --> P2 | N=200 --> 0 | Trial completion date: May 2025 --> Sep 2025 | Not yet recruiting --> Withdrawn Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
OBINUTUZUMAB AS DEBULKING THERAPY FOR A SUCCESSFUL DELIVERED OF FIXED-DURATION VENETOCLAX () - May 15, 2024 - Abstract #EHA2024EHA_1754;
The patient underwent intravenous (IV) hydration, and daily urolithic therapy with rasburicase 7...Thereaction was treated with hydrocortisone 200 mg, chlorphenamine 10 mg, paracetamol 1000 mg, ondansetron8 mg, furosemide 20 mg and O2 supportive therapy... With proper support therapy, Obinutuzumab associated with Venetoclax represented a life-saving treatment, isable to normalize the blood counts and achieve a complete response also in CLL-patients with an extremelyhigh risk of TLS.
- |||||||||| olanzapine / Generic mfg.
Journal: Gender differences in cognitive improvements after two months of atypical antipsychotic treatment in first episode schizophrenia. (Pubmed Central) - May 14, 2024
There was no significant difference in age of onset, education years, PANSS scores, duration of untreated psychosis and Olanzapine equivalent doses between male and female patients (all p > 0.05)...Our findings revealed gender differences of cognitive improvements in patients with FES after 2-month treatment. It provides new evidence for gender differences in cognitive symptoms of schizophrenia, and also provides preliminary clues for further individualized cognitive intervention strategies.
- |||||||||| fluoxetine / Generic mfg.
Biomarker, Journal: The impacts of natural product miltirone and the CYP2D6 pharmacogenetic phenotype on fluoxetine metabolism. (Pubmed Central) - May 14, 2024
Among these variants, CYP2D6*92 and CYP2D6*96/Q424X were found to be catalytically inactive for fluoxetine metabolism, five variants (CYP2D6*89/L142S, *97/F457L, *R497, *V342M and *R344Q) exhibited markedly increased clearance values (>125.07%) and seven variants (CYP2D6*2, *10, *87/A5V, *93/T249P, *E215K, *R25Q and *R440C) exhibited significantly decreased clearance values (from 6.62% to 66.79%) compared to those of the wild-type. Our results suggest that more attention should be given to subjects in the clinic who take fluoxetine and also carry one of these infrequent CYP2D6 alleles or are coadministered drugs containing miltirone.
- |||||||||| clomipramine / Generic mfg., risperidone / Generic mfg., escitalopram / Generic mfg.
Journal: The anti-inflammatory effects of antidepressants on colitis. (Pubmed Central) - May 13, 2024
Clomipramine showed the best anti-inflammatory effect compared to Escitalopram and Risperidone. Therefore, clomipramine showed the best relieving effect on inflammation of ulcerative colitis in rats.
- |||||||||| fluoxetine / Generic mfg.
Journal: Suanzaoren decoction exerts its antidepressant effect via the CaMK signaling pathway. (Pubmed Central) - May 13, 2024
Model rats were given intragastric administration of SZRD or fluoxetine every morning once a day...Our findings demonstrated that SZRD significantly improved the mood of depressed rats. This indicates that SZRD, by modulating the CaMK signaling system, may alleviate depressive symptoms and lessen work and life-related pressures.
- |||||||||| duloxetine / Generic mfg.
Journal: The effect of duloxetine on stress urinary incontinence. (Pubmed Central) - May 13, 2024
This indicates that SZRD, by modulating the CaMK signaling system, may alleviate depressive symptoms and lessen work and life-related pressures. Duloxetine is therapeutically effective for SUI
- |||||||||| chlorpromazine / Generic mfg.
Journal: Determination of 12 prohibited veterinary drug residues in pig urine by ultra high performance liquid chromatography-tandem mass spectrometry (Pubmed Central) - May 13, 2024
A method was established for the simultaneous detection of 12 prohibited veterinary drugs, including ?2-receptor agonists, nitrofuran metabolites, nitroimidazoles, chlorpromazine, and chloramphenicol, in pig urine...The mean recoveries and RSDs at 1, 2, and 10 times the LOQ were 83.6%-115.3% and 2.20%-12.34%, respectively. The proposed method has the advantages of high sensitivity, good stability, and accurate quantification; thus, it is suitable for the simultaneous determination of the 12 prohibited veterinary drug residues in pig urine.
- |||||||||| lorazepam / Generic mfg., haloperidol / Generic mfg.
Trial completion date, Metastases: NCI-2018-02438: Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care (clinicaltrials.gov) - May 13, 2024
P2/3, N=110, Active, not recruiting,
The proposed method has the advantages of high sensitivity, good stability, and accurate quantification; thus, it is suitable for the simultaneous determination of the 12 prohibited veterinary drug residues in pig urine. Trial completion date: May 2024 --> May 2025
- |||||||||| chloroquine phosphate / Generic mfg., imipramine / Generic mfg.
Preclinical, Journal: Elucidating Gender-Specific Distribution of Imipramine, Chloroquine, and Their Metabolites in Mice Kidney Tissues through AP-MALDI-MSI. (Pubmed Central) - May 11, 2024
Interestingly, they showed a characteristic distribution in the medulla of the female kidney, while almost no distributions were observed in the same areas of the male kidney. For the first time, our study revealed that the distributions of imipramine, chloroquine, and their metabolites were different in male and female kidneys.
- |||||||||| Adlumiz (anamorelin) / Helsinn, Ono Pharma
Review, Journal: Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions. (Pubmed Central) - May 11, 2024
In Japan, the clinical practice has changed based on the availability of Anamorelin, a ghrelin receptor agonist that improved lean body mass, weight, and appetite-related quality of life (QoL) compared to a placebo, in phase III trials...In the future, a single therapeutic agent or perhaps multiple medications targeting the various mechanisms of CC may prove to be an effective strategy. Ideally, these medications should be incorporated into a multimodal interdisciplinary approach that includes exercise and nutrition.
- |||||||||| escitalopram / Generic mfg.
Clinical, Journal: Impact of Baduanjin exercise combined with rational emotive behavior therapy on sleep and mood in patients with poststroke depression: A randomized controlled trial. (Pubmed Central) - May 10, 2024
Future studies need to enroll larger samples, include randomized controlled study designs, create more uniform protocols for combined treatment delivery, and explore mechanisms and predictors of change. Baduanjin exercise combined with rational emotive behavior therapy effectively improves the mood and sleep status of patients with PSD; It increases the serum levels of 5-HT and BDNF while reducing the level of serum proinflammatory factor IL-6; additionally, the intervention alleviates the degree of neurological impairment, upgrades the ability of daily living, and improves the quality of life.
- |||||||||| Tapit (granisetron) / VHB Life Sci
Preclinical, Journal, Tumor cell: Methods for assessing and removing non-specific photoimmunotherapy damage in patient-derived tumor cell culture models. (Pubmed Central) - May 10, 2024
Baduanjin exercise combined with rational emotive behavior therapy effectively improves the mood and sleep status of patients with PSD; It increases the serum levels of 5-HT and BDNF while reducing the level of serum proinflammatory factor IL-6; additionally, the intervention alleviates the degree of neurological impairment, upgrades the ability of daily living, and improves the quality of life. In this study, we tested two primary ovarian tumor cell lines that are intrinsically chemoresistant, yet ultrasensitive to BPD-PDT such that small amounts of free BPD (a
- |||||||||| memantine / Generic mfg.
Review, Journal: Spectrum of NMDA Receptor Variants in Neurodevelopmental Disorders and Epilepsy. (Pubmed Central) - May 10, 2024
Currently, targeted treatment options for GRIN-related diseases are limited. However, treatment with memantine has been reported to significantly reduce seizure frequency in a few individuals with developmental and epileptic encephalopathies harboring de novo gain-of-function GRIN2A missense variants, and supplementary treatment with L-serine has been associated with improved motor and cognitive performance as well as reduced seizure frequency in patients with GRIN2B loss-of-function missense variants as well as GRIN2A and GRIN2B null variants.
- |||||||||| metadoxine / Generic mfg.
Journal: Alcohol use disorders and liver fibrosis: an update. (Pubmed Central) - May 10, 2024
Treatment drugs include silybin, metadoxine and adenosyl methionine...Other drugs, with promising antifibrotic effects, are now being studied. This review deals with the clinical and pathogenetic aspects of alcohol-related liver fibrosis and suggests possible future strategies to prevent cirrhosis.
- |||||||||| Journal: Efficacy of antipsychotics in delusional infestation. (Pubmed Central) - May 10, 2024
Amisulpride and risperidone were associated with a higher treatment response than quetiapine, aripiprazole and olanzapine. Amisulpride and risperidone should therefore be considered the first-line treatment options in DI patients.
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts. (Pubmed Central) - May 10, 2024
Benzodiazepines and related drugs (aHR=1.29, 95% CI: 1.24-1.34) and mirtazapine (aHR=1.17, 95% CI: 1.07-1.29) were associated with an increased risk of relapse. These data indicate that, in the maintenance treatment of PD, bupropion, vortioxetine, venlafaxine, any LAI, clozapine, and only few specific antidepressant-antipsychotic combinations are
- |||||||||| clozapine / Generic mfg.
Journal: Schizophrenia and schizoaffective disorder: Length of stay and associated factors. (Pubmed Central) - May 10, 2024
Male gender (p = 0.018), being unmarried (p = 0.006), treatment resistant (p < 0.001) and on clozapine (p = 0.009) were factors found to have a significant association with long-stay admissions...This study highlights factors associated with long-stay admissions in patients with schizophrenia and schizoaffective disorder. More research is needed into whether increased access to community-based services, such as residential and daycare facilities, outpatient substance rehabilitation programmes and dual diagnosis clinics, could translate into shorter admissions, less frequent relapses and improved outcomes in this population.
- |||||||||| progesterone / Generic mfg., paroxetine / Generic mfg.
Preclinical, Journal: Effect of Shenqi Jieyu formula on inflammatory response pathway in hippocampus of postpartum depression rats. (Pubmed Central) - May 10, 2024
SJF, paroxetine hydrochloride and sEH inhibitor (AUDA) were used to treat PPD rats for 3 weeks...SJF reversed the gene expression changes of COX-2, TNF-?, and IL-1?. SJF may have an analogous effect as sEH inhibitor to relieve depressive symptoms by suppressing inflammatory signaling pathways in hippocampi of PPD rats, which involves AA metabolic pathway and NF-?B signal pathway.
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Evaluation of multitarget drugs on the expression of cocaine-induced locomotor sensitization in male rats: A comparative study. (Pubmed Central) - May 10, 2024
SJF may have an analogous effect as sEH inhibitor to relieve depressive symptoms by suppressing inflammatory signaling pathways in hippocampi of PPD rats, which involves AA metabolic pathway and NF-?B signal pathway. Here we compare the efficacy of mirtazapine (MIR), pindolol (PIN), fluoxetine (FLX), risperidone (RIS), trazodone (TRZ), ziprasidone (ZPR), ondansetron (OND), yohimbine (YOH), or prazosin (PRZ), to reduce long-term cocaine-induced locomotor activity and the expression of cocaine-induced locomotor sensitization in rats...After each administration, locomotor activity for each animal was recorded for 30
- |||||||||| fluoxetine / Generic mfg.
Journal: Parietal-Frontal Pathway Controls Relapse of Fear Memory in a Novel Context. (Pubmed Central) - May 10, 2024
In addition, we found that parvalbumin-expressing interneurons controlled novel context-dependent fear renewal, which was blocked by the chronic administration of fluoxetine. Our findings highlight the PPC-to-ACC pathway in mediating the relapse of extinguished fear in novel contexts, thereby contributing significant insights into the intricate neural mechanisms that govern fear renewal.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Does the setting for intradetrusor onabotulinumtoxinA injection for management of overactive bladder matter? (Pubmed Central) - May 10, 2024
Patients in the OR group had a higher reported improvement as compared to the in-office group (81.4% vs. 73.3%, P = 0.03). In this cohort study of patients with OAB undergoing intradetrusor onabotulinumtoxinA injections, post procedural subjective improvement was high regardless of the setting in which the procedure was performed.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial initiation date, Trial primary completion date: Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids (clinicaltrials.gov) - May 10, 2024
P=N/A, N=40, Not yet recruiting,
More studies are needed for a definite conclusion. Trial completion date: Jul 2024 --> Oct 2024 | Initiation date: Mar 2024 --> Aug 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Retrospective data, Journal: The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study. (Pubmed Central) - May 10, 2024
Our updated analyses of the up-to-date evidence regarding monotherapies for male AGA showed that the oral form of 5-alpha reductase inhibitors are more effective than oral minoxidil and other newer agents like Botox, microneedling, and photobiomodulation. Our findings can better inform clinical decision making and design of future research studies.
- |||||||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed, Trial primary completion date: A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD (clinicaltrials.gov) - May 10, 2024
P2, N=40, Active, not recruiting,
Our findings can better inform clinical decision making and design of future research studies. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2024 --> Jul 2024
|
